Peer-reviewed veterinary case report
Lomustine after radiation for bone cancer in dogs
By Duffy, Megan E et al.·Published in The Canadian veterinary journal = La revue veterinaire canadienne·2018·Department of Veterinary Clinical Sciences, United States·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Metronomic administration of lomustine following palliative radiation therapy for appendicular osteosarcoma in dogs.
- Species:
- dog
Plain-English summary
A group of dogs with appendicular osteosarcoma (a type of bone cancer) received palliative radiation therapy to help manage their pain. Some of these dogs were also given a medication called lomustine to see if it would help them live longer. However, the study found that while lomustine was tolerated well, it did not significantly increase the length of survival compared to dogs that only received radiation therapy. Both groups lived for about six months on average, with no major differences in their outcomes.
People also search for: dog osteosarcoma treatment · palliative care for dogs with cancer · lomustine for dogs bone cancer
Abstract
The purpose of this study was to determine if metronomic administration of lomustine following palliative radiation therapy (RT) improved length of palliation and therefore survival in dogs with appendicular osteosarcoma compared to treatment with palliative radiation alone. A search of medical records identified dogs with appendicular osteosarcoma, treated with palliative RT (2 fractions of 8 Gray in a 24 hour time frame, day 0 and day 1; or day 0, 6 hours apart). Data collected included signalment, history, clinical signs, physical examination findings, clinicopathologic abnormalities, extent of disease, response, toxicity, other therapy, survival time, and whether dogs received metronomic lomustine (ML) or not. Of 86 patients, 43 received ML while 43 did not. Median survival time (MST) was not significantly different (= 0.84), at 184 +/- 17 days for patients which received ML, and 154 +/- 20 days for those which did not. Metronomic lomustine administration was well-tolerated, but it did not improve survival in dogs with palliatively treated osteosarcoma.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/29386671/